Special Issue "New Cancer and Osteoporosis Therapies and Osteonecrosis of the Jaws, Volume Ⅱ"

A special issue of Dentistry Journal (ISSN 2304-6767).

Deadline for manuscript submissions: 31 October 2018

Special Issue Editor

Guest Editor
Prof. Dr. Dr. Christian Walter

Mediplus - Praxisklinik, MKG-Chirurgie, Haifa-Allee 20, 55128 Mainz, Germany
Website | E-Mail
Phone: 06131 490 808 5/06131 490 808 9
Fax: +49 6131 17 6602
Interests: bisphosphonate associated osteonecrosis; osteomyelitis; squamous cell carcinoma; traumatology; implantology; bisphosphonate; RankL

Special Issue Information

Dear Colleagues,

More than 10 years ago, bisphosphonate-associated osteonecrosis was described for the first time, opening a new research field describing epidemiologic and patho-etiologic data, as well as prevention, diagnostic, and therapy regimes for this new disease. In 2006, more than 150 articles on this topic were published, and since 2009 more than 200 new articles have been listed in PubMed each year, showing the progress of research in this area. In recent years, new active ingredients have been developed and implemented into anti-cancer and osteoporosis therapy, such as RankL inhibitors and tyrosine kinase inhibitors, which lead to osteonecrosis as well.

This Special Issue is interested in all aspects of all dental specialties dealing with this topic. In addition to basic research regarding pathology, prevention, and treatment, clinical topics are of interest. How is dental treatment affected by anti-resorptive therapies, e.g., surgical procedures (tooth extractions, implantology, etc.), periodontal, orthodontic, or endodontic treatment?

Dr. Christian Walter
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Dentistry Journal is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Medication associated/related/induced osteonecrosis of the jaws
  • Bisphosphonate
  • RankL inhibitor
  • Tyrosine kinase inhibitors
  • VEGF inhibitors
  • Epidemiology
  • Prevalence and incidence
  • Etiology and pathology
  • Microbiological factors
  • Influence of bisphosphonates/medication on the bone
  • Influence of bisphosphonates/medication on the immune system
  • Influence of bisphosphonates/medication on soft tissues
  • Risk factors
  • Prevention
  • Diagnosis
  • Histology
  • Therapy
  • Periodontal treatment
  • Dental implants
  • Orthodontic treatment
  • Complications
  • Animal models

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Other

Open AccessComment Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
Dent. J. 2018, 6(3), 42; https://doi.org/10.3390/dj6030042
Received: 22 July 2018 / Revised: 22 August 2018 / Accepted: 27 August 2018 / Published: 1 September 2018
PDF Full-text (197 KB) | HTML Full-text | XML Full-text
Abstract
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such
[...] Read more.
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. Full article
Open AccessCase Report Meth Mouth—A Growing Epidemic in Dentistry?
Dent. J. 2017, 5(4), 29; https://doi.org/10.3390/dj5040029
Received: 13 August 2017 / Revised: 9 September 2017 / Accepted: 19 September 2017 / Published: 30 October 2017
PDF Full-text (40500 KB) | HTML Full-text | XML Full-text
Abstract
In the past two decades, the synthetic style and fashion drug “crystal meth” (“crystal”, “meth”), chemically representing the crystalline form of the methamphetamine hydrochloride, has become more and more popular in the United States, in Eastern Europe, and just recently in Central and
[...] Read more.
In the past two decades, the synthetic style and fashion drug “crystal meth” (“crystal”, “meth”), chemically representing the crystalline form of the methamphetamine hydrochloride, has become more and more popular in the United States, in Eastern Europe, and just recently in Central and Western Europe. “Meth” is cheap, easy to synthesize and to market, and has an extremely high potential for abuse and dependence. As a strong sympathomimetic, “meth” has the potency to switch off hunger, fatigue and, pain while simultaneously increasing physical and mental performance. The most relevant side effects are heart and circulatory complaints, severe psychotic attacks, personality changes, and progressive neurodegeneration. Another effect is “meth mouth”, defined as serious tooth and oral health damage after long-standing “meth” abuse; this condition may become increasingly relevant in dentistry and oral- and maxillofacial surgery. There might be an association between general methamphetamine abuse and the development of osteonecrosis, similar to the medication-related osteonecrosis of the jaws (MRONJ). Several case reports concerning “meth” patients after tooth extractions or oral surgery have presented clinical pictures similar to MRONJ. This overview summarizes the most relevant aspect concerning “crystal meth” abuse and “meth mouth”. Full article
Figures

Figure 1

Back to Top